Jakafi is a kinase inhibitor indicated for treatment of: • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelof • polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. • steroid-refrac.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of JAKAFI (ruxolitinib) tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the JAKAFI (ruxolitinib) tablets medicine cost price in India.
The order for JAKAFI (ruxolitinib) tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Ruxolitinib is used to treat myelofibrosis or polycythemia vera, which are bone marrow disorders that that affect your body's ability to produce blood cells.
JAKAFI® (ruxolitinib) tablets, for oral use Initial U.S. Approval: 2011
Generic Name: ruxolitinib
Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg
60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand JAKAFI (ruxolitinib) tablets on prescription and Import License in Patient's Name only.
For overseas patients, JAKAFI (ruxolitinib) tablets can be made available in Send your enquiry to find JAKAFI (ruxolitinib) tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For JAKAFI (ruxolitinib) tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Ruxolitinib Shows Noteworthy Responses in Patients With Rare Leukemias
Ongoing Research Poised to Add Options for Myelofibrosis Treatment For More Details